1. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer
- Author
-
Andrea Decensi, Jennifer Gjerde, Debora Macis, Gunnar Mellgren, Agnita Rajasekaran, Valentina Aristarco, Bernardo Bonanni, Aliana Guerrieri-Gonzaga, Harriet Johansson, Sara Gandini, Davide Serrano, Clark V. Williard, and Matteo Lazzeroni
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.drug_class ,Estrogen receptor ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Breast cancer ,Exemestane ,Internal medicine ,Genotype ,Genetics ,medicine ,Aromatase ,Pharmacology ,biology ,business.industry ,Proportional hazards model ,medicine.disease ,030104 developmental biology ,chemistry ,Estrogen ,biology.protein ,Molecular Medicine ,business ,Estrogen receptor alpha - Abstract
Polymorphisms of genes involved in estrogen synthesis have been linked to breast cancer risk, prognosis, and treatment response. We investigated the prognostic impact of a deletion spanning the entire UGT2B17 gene (UGT2B17*2) and genetic variants of the aromatase CYP19A1 and estrogen receptor α (ESR1) in 125 postmenopausal women with ER-positive breast cancer enrolled in a randomized pre-surgical trial. The UGT2B17*2 was estimated by copy number variation assays and the CYP19A1 rs10046/rs4646 and ESR1 rs2077647/rs2234693/rs9340799 by TaqMan allelic discrimination assays. Serum exemestane/17-hydroxy exemestane were determined by MS and estrone (E1)/estradiol (E2)/ by GC-MS/MS. The association of genetic polymorphisms with “any event” was assessed by the Cox proportional hazards models adjusted for confounders. The UGT2B17*2 was associated with higher levels of 17-hydroxy exemestane (P = 0.04) and better prognosis (HR = 0.45; 95% CI: 0.20–1.01; P = 0.05) compared with homozygote UGT2B17 wt. The CYP19A1 rs10046 A and rs4646 C alleles were associated with higher estrogen levels: rs10046 AA vs. AG/GG genotypes had median E1 of 35.9 vs. 27.4 pg/mL (P = 0.05) and E2 of 7.57 vs. 3.9 pg/mL (P
- Published
- 2019